Clinical Trials Browser

NIH × Lymphoma, Extranodal NK-T-Cell × Etoposide × Clear all

Lymphoma, Lymphoma, T-Cell, Lymphoma, Extranodal NK-T-Cell

NCT01445535 2021-11-03

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas

Subcutaneous panniculitis-like T-cell lymphoma, Lymphoma, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell

NCT00101205 2014-02-24

Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma

Phase 1 Terminated

40 enrolled

DermatologicLymphoidOther hematologic neoplasmSarcoma

Burkitt Lymphoma, Immunoblastic Lymphadenopathy, Leukemia, Hairy Cell, Mycosis Fungoides, Recurrence, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Dendritic Cell Sarcoma, Interdigitating, Intraocular Lymphoma

Clinical Trials

Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas

Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma